References
- Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
- Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol.28(7), 1254–1261 (2010).
- Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
- Saridaki Z, Tzardi M, Papadaki C et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS One6(1), e15980 (2011).
- Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J. Mol. Diagn.10(6), 493–495 (2008).
- Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J. Mol. Diagn.12(1), 43–50 (2010).
- Oliner K, Juan T, Suggs S et al. A comparability study of 5 commercial KRAS tests. Diagn. Pathol.5, 23 (2010).
- Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH. Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn. Mol. Pathol.20(3), 158–165 (2011).
- Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol.27(7), 1130–1136 (2009).
- Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol.9(10), 962–972 (2008).
- Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res.17(14), 4901–4914 (2011).
- Bando H, Yoshino T, Tsuchihara K et al.KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br. J. Cancer105(3), 403–406 (2011).